Laboratorio Teuto
Laboratório Teuto is a privately held Brazilian pharmaceutical manufacturer founded in 1947, producing generics, reference drugs, OTC products, biosimilars, and supplements from its Anápolis, Goiás headquarters and serving more than 95% of Brazilian pharmacies across 24 states.
- Company typePrivate
- Founded1947
- HeadquartersAnápolis, Brazil
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Laboratorio Teuto does
Laboratório Teuto is a privately held Brazilian pharmaceutical manufacturer headquartered in Anápolis, Goiás, with a stated 79-year operating history (founded 1947) and a 4,000+ workforce. The company operates the most complete pharmaceutical manufacturing park in Latin America, producing generics, reference (branded) medicines, similar/equivalent medicines, over-the-counter (MIP) products, cosmetics, dietary supplements, hospital-grade antimicrobials, and an emerging oncology biosimilars line under the biOncologia Teuto business unit. Its portfolio exceeds 560 registered products, and it reports leadership positions across 24 of Brazil's 27 states and coverage of more than 95% of Brazilian pharmacies. Recent capacity additions include two Fette P3030 tablet presses (up to 1 million tablets/hour each), a new Purified Water system (8,000 L/hour), a new regional distribution center in Espírito Santo (4,170 pallets / 200,000 boxes/month), and a paperless manufacturing program (e-TOP) developed with Siemens.
Teuto makes money primarily through B2B pharmaceutical sales — generic medications (legally required to be at least 35% below reference prices), reference drugs, OTC products, biosimilars, and supplements — routed through three principal channels: national distributors (mid-market), direct relationships with hospital networks and large pharmacy chains (enterprise), and channel sales to independent pharmacies. Distribution architecture, brand equity built around the tagline 'Se é Teuto, é de Confiança', and regulatory compliance (ANVISA BPF, ISO 9000, ASME BPE) form the basis of customer acquisition and retention. International expansion via export channels spans five continents, with a flagship MOU with Hong Kong's Zhaoke Ophthalmology (signed at BIO 2026) targeted at the ophthalmology therapeutic segment. Operating model is fully self-financed — no external PE/VC rounds are disclosed — under continued Melo-family stewardship, with Ítalo Melo as President of the Administrative Council and Marcelo Henriques Leite as CEO.
Laboratorio Teuto firmographics
Firmographics- Name
- Laboratorio Teuto
- Legal name
- Laboratório Teuto
- Website
- https://teuto.com.br
- Company type
- Private
- Founded year
- 1947
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Laboratório Teuto is a privately held Brazilian pharmaceutical manufacturer founded in 1947, producing generics, reference drugs, OTC products, biosimilars, and supplements from its Anápolis, Goiás headquarters and serving more than 95% of Brazilian pharmacies across 24 states.
- Ownership category
- akta.pro rank
Laboratorio Teuto industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where Laboratorio Teuto is headquartered
LocationHeadquarters
- HQ city
- Anápolis
- HQ country
- Brazil
- HQ region
- Latin America
Offices2 records
Markets served
Laboratorio Teuto business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Generic Medications: Production and sale of generic medications (equivalentes), one of the first companies licensed to produce generics in Brazil after the 1999 law. Generics must be at least 35% cheaper than reference drugs.
- Reference Medications: Branded pharmaceutical products that serve as benchmarks for generic equivalents.
- Biosimilars (biOncologia): Entry into oncology biosimilars market through dedicated business unit, offering medications like Pegneneucyte (biosimilar pegfilgrastim) and Simbeva (biosimilar bevacizumab) at more accessible prices.
- Over-the-Counter (MIP) Products: Medications exempt from prescription including allergy treatments, topical gels, and health products.
- Cosmetics and Health Products: Cosmeceutical and health product lines for retail distribution.
- Supplements: Nutritional and dietary supplements for health maintenance.
Go-to-market motion1 record
Distribution channels6 records
Marketing channels7 records
Laboratorio Teuto product offering
Product offeringCore offering
Laboratorio Teuto manufactures and distributes a broad pharmaceutical portfolio of 560+ registered products including generic medicines, reference drugs, similar equivalents, biosimilars (oncology), over-the-counter medications, hospital-grade antimicrobials, cosmetics, health products, and dietary supplements. The company operates the most complete pharmaceutical park in Latin America, located in Anápolis, Goiás, producing 741 million pharmacotechnical units per month at historic capacity, with B2B distribution across Brazil reaching 95%+ of pharmacies and exports to 5 continents.
Product overview
Laboratório Teuto operates as a comprehensive pharmaceutical company with Brazil's most complete pharmaceutical manufacturing park in Latin America. The portfolio encompasses generic medicines (including the first generic combination for hypertension - Telmisartan + Hydrochlorothiazide), reference medicines, similar/equivalent medicines, biosimilars through biOncologia unit (Pegneneucyte/Pegfilgrastim and Simbeva/Bevacizumab), over-the-counter medicines (antihistamines, topical analgesics), health products (Biolágrima ocular lubricant), cosmetics, nutritional supplements, and hospital-grade antimicrobials. With over 560 registered products and almost 8 decades of operation, the company serves the entire Brazilian pharmaceutical retail, hospital, and distribution channels.
Differentiator
Problem solved
Functional benefit
Brands
- biOncologia Teuto: A specialized business unit focused on oncology biosimilars, offering products like Pegneneucyte (Biosimilar Pegfilgrastim) and Simbeva (Biosimilar Bevacizumab).
- Teuto Especialidades
- CEI Walterci de Melo
Products and services
- Generic Medications (Medicamentos Genéricos) Bioequivalent generic medicines offered at minimum 35% below reference drug prices, covering multiple therapeutic categories including cardiovascular, allergy, and chronic disease treatments. Sold to retail pharmacies, distributors, and institutional buyers.
- Reference Medications (Medicamentos de Referência) Brand-name reference medicines that serve as benchmarks for generic equivalents, representing original pharmaceutical formulations across multiple therapeutic areas.
- Similar/Equivalent Medications (Medicamentos Similares/Equivalentes) Similar medicines that contain the same active ingredients as reference products, marketed at competitive prices within the Brazilian pharmaceutical market.
- biOncologia Teuto Biosimilars (Pegneneucyte and Simbeva) Biosimilar medicines for oncology treatment offered through the biOncologia Teuto unit, including Pegneneucyte (Biosimilar Pegfilgrastim) and Simbeva (Biosimilar Bevacizumab) at more accessible prices compared to reference biologics, representing entry into high-complexity biologic drugs market.
- Over-the-Counter Medications (MIPs) OTC medicines exempt from prescription including antihistamines (Desloratadine, Fexofenadine, Dexchlorpheniramine Maleate), topical analgesics (Arnica Gel, Fenaflan Ice), and combination products for retail pharmacy sale.
- Health Products (Biolágrima Ocular Lubricant) Health products including ocular lubricants such as Biolágrima, an artificial tear solution for dry eye relief and contact lens comfort.
- Cosmetics Cosmetic products complementing the health and wellness portfolio, distributed through pharmacy retail channels.
- Dietary Supplements (Suplementos Alimentares) Nutritional supplements expanding the company's complete health solutions portfolio for pharmacy retail distribution.
- Hospital-Grade Antimicrobials (Piperacillin + Tazobactam, Bepeben) Hospital-grade antimicrobials including Piperacillin + Tazobactam (broad-spectrum antibiotic) and Bepeben (antibiotic for syphilis treatment) targeting institutional healthcare market and public/private hospital procurement.
- Telmisartan + Hydrochlorothiazide (Telmisartana + Hidroclorotiazida) Generic fixed-dose combination antihypertensive medication available in three dosages (40mg+12.5mg, 80mg+12.5mg, 80mg+25mg), combining angiotensin II receptor antagonist with diuretic for improved blood pressure control in patients with hypertension.
Quantifiable outcome
- 19.63% revenue growth in 2023 to R$ 1.54 billion
- +5 more outcomes
Companies that use Laboratorio Teuto
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
Laboratorio Teuto technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Laboratorio Teuto partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship, core and minor.
- Zhaoke OphthalmologyflagshipMOU signed at BIO 2026 for ophthalmology market entry. Partnership enables Teuto to expand into the ophthalmology therapeutic segment, leveraging Zhaoke's expertise in eye disease treatments.
- SiemenscorePartnership for e-TOP (Teuto Operation Without Paper) digital transformation project. Siemens provides technology solutions for paperless manufacturing operations, digital documentation, and process automation in pharmaceutical production.
- VittudecoreMental health support partnership providing psychological services to employees through Teuto Cuida program. Vittude connects company with qualified psychologists for personalized support since COVID-19 pandemic reinforcement.
- Instituto BullaminorTraining partnership for 'Seu Negócio Mais Lucrativo' program that trains small and medium pharmacy retailers on business management best practices.
- Instituto Euvaldo Lodi (IEL)coreInova Talentos program connecting master's and PhD researchers with pharmaceutical R&D projects. Winner of 1st place in two categories at 21st Prêmio IEL de Talentos 2025.
- UniEvangélica (Universidade Evangélica de Goiás)minorAcademic partnership recognized with 'Amigos da Ciência' award at IV Prêmio Mérito Científico. Collaboration between industry and academia for scientific development.
- LabCentralminorCross-border startup support partnership with HKSTP enabling international startup collaboration and market access support.
- Pharmacy Chains and AssociationscoreStrong partnerships with pharmacy networks including Farmarcas (1,600+ associated pharmacies), Agafarma (500+ stores), and participation in major pharmacy events like Farmatrend and Farmarcas meetings.
Scale indicators19 records
Recent moves12 records
Expansion highlights6 records
Laboratorio Teuto competitors and assessment
Company assessmentDirect peers
- Medley (Sanofi): Historically one of Brazil's largest generic drug manufacturers, now part of Sanofi, competing directly with Teuto in retail generics, hospital injectables, and OTC. Comparable product breadth and pharmacy distribution model.
- Cristália Produtos Químicos Farmacêuticos: Brazilian pharmaceutical and hospital-focused manufacturer with strong footprint in injectables, anesthetics, and hospital products. Closely comparable to Teuto's hospital antimicrobials and institutional segment.
- Prati-Donaduzzi: Large Brazilian generics manufacturer with broad retail and hospital portfolio. Similar in scale and channel approach to Teuto, competing directly for pharmacy and SUS contracts.
- EMS Pharma: Brazil's largest pharmaceutical company and the dominant domestic generics manufacturer, with a similar broad portfolio across generics, branded drugs, OTC, and hospital specialties. EMS is the primary share-of-throat competitor for Teuto in the Brazilian retail pharmacy channel.
- Eurofarma Laboratórios: Large Brazilian pharmaceutical manufacturer with comparable diversified portfolio spanning generics, branded, hospital, and oncology. Competes head-to-head with Teuto across retail and institutional channels in Brazil and increasingly across Latin America.
- Biolab Farmacêutica: Brazilian pharmaceutical company with strengths in prescription brands, generics, and dermatology/cosmetics. Overlaps with Teuto in generic manufacturing, OTC, and hospital segments, and competes for the same pharmacy shelf space.
- Aché Laboratórios: Major Brazilian pharmaceutical company with strong presence in branded generics, prescription, and OTC segments. Operates a similar B2B model serving pharmacy chains and hospitals, making it a direct domestic peer to Teuto.
Broad incumbents
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad portfolio of generics, biosimilars, and specialty medicines. Comparable to Teuto in generics and biosimilar oncology ambitions, though operating at vastly greater global scale.
- Sandoz (Novartis): Global leader in generics and biosimilars spun out of Novartis. Directly comparable to Teuto in finished-dosage generic manufacturing and emerging biosimilar pipeline, and a benchmark for the strategic and economic model Teuto aspires to in specialty/biosimilars.
Emerging players
- Aurobindo Pharma: Large Indian generic and active pharmaceutical ingredient manufacturer with growing global and emerging-market footprint. Comparable to Teuto as a generics-led manufacturer with international expansion ambitions and increasing biosimilar activity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks1 record
Key highlights7 records
Customer concentration
Laboratorio Teuto social profiles
Digital presenceLaboratorio Teuto compliance and trust
Trust signalCompliance2 records
Laboratorio Teuto financial estimates
Financial estimateRevenue estimate
Valuation estimate
Laboratorio Teuto leadership team
Management profileNumber of profiles
Profiles12 records
Laboratorio Teuto funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Laboratorio Teuto M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Laboratorio Teuto
What does Laboratorio Teuto do?
Laboratorio Teuto manufactures and distributes a broad pharmaceutical portfolio of 560+ registered products including generic medicines, reference drugs, similar equivalents, biosimilars (oncology), over-the-counter medications, hospital-grade antimicrobials, cosmetics, health products, and dietary supplements. The company operates the most complete pharmaceutical park in Latin America, located in Anápolis, Goiás, producing 741 million pharmacotechnical units per month at historic capacity, with B2B distribution across Brazil reaching 95%+ of pharmacies and exports to 5 continents.
Is Laboratorio Teuto a public or private company?
Laboratorio Teuto is a private company. It is classified as family owned and is currently operating.
When was Laboratorio Teuto founded?
Laboratorio Teuto was founded in 1947. It employs 1,001 to 5,000 people.
Where is Laboratorio Teuto based?
Laboratorio Teuto is headquartered in Anápolis, Brazil, in the Latin America region.
How does Laboratorio Teuto make money?
Six revenue lines are on record. Generic Medications are the primary driver. The others are reference Medications, biosimilars (biOncologia), over-the-Counter (MIP) Products, cosmetics and Health Products and supplements.
Who are Laboratorio Teuto's main competitors?
Direct peers on record are Medley (Sanofi), Cristália Produtos Químicos Farmacêuticos, Prati-Donaduzzi, EMS Pharma, Eurofarma Laboratórios, Biolab Farmacêutica and Aché Laboratórios. Broad incumbents are Teva Pharmaceutical Industries and Sandoz (Novartis). Aurobindo Pharma is listed as an emerging player.
Does Laboratorio Teuto have an API?
No public API is recorded for Laboratorio Teuto.
What industry is Laboratorio Teuto in?
Laboratorio Teuto's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.